Justine Marsolier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Justine Marsolier has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
- Céline Vallot
Institut Curie
15 shared publications - Elisabetta Marangoni
Translational Research Department, Institut Curie
14 shared publications - Pacôme Prompsy
CNRS UMR3244, Institut Curie, PSL University, Paris, France
14 shared publications - Ahmed Dahmani
Translational Research Department, Institut Curie, PSL University, Paris, France
12 shared publications - Christophe Huret
Université Paris Cité, CNRS UMR7216, Epigenetic and Cell Fate, Paris, France
12 shared publications - Damarys Loew
Institut Curie, PSL Research University, CurieCoreTech Mass Spectrometry Proteomics, Paris, France
12 shared publications
Latest Publications
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
Characterization of the persister state commonalities in vivo
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
Characterization of the persister state commonalities in vivo
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
Expression of transcription factors predicted to regulate activation of the persister expression program in vivo
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
Expression of transcription factors predicted to regulate activation of the persister expression program in vivo
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
Identification of FOSL1 as a key regulator of the persister expression program in vitro
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
Identification of FOSL1 as a key regulator of the persister expression program in vitro
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
FOSL1 expression increases the capacity of the cells to tolerate drug insult in vitro
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
FOSL1 expression increases the capacity of the cells to tolerate drug insult in vitro
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Data from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
Acquisition of resistance to anticancer therapies is a multistep process initiated by the survival of drug-tolerant persister cells. Accessibility of drug-tolerant persister cells in patients is limited, which has hindered understanding the mechanisms driving their emergence. In this study, using multiple patient-derived models to isolate persister cells, we showed that these cells are transcriptionally plastic in vivo and return to a common treatment naïve–like state upon relapse, regardless of treatment. Hallmarks of the persister state in triple-negative breast cancer (TNBC) across treatment modalities included high expression of basal keratins together with activation of stress response and inflammation pathways. These hallmarks were also activated in HER2+ breast and lung cancer cells in response to targeted therapies. Analysis of gene regulatory networks identified AP-1, NF-κB, and IRF/STAT as the key drivers of this hallmark persister state. Functionally, FOSL1, an AP-1 member, drove cells to the persister state by binding enhancers and reprogramming the transcriptome of cancer cells. On the contrary, cancer cells without FOSL1 had a decreased ability to reach the persister state. By defining hallmarks of TNBC persistence on multiple therapies, this study provides a resource to design effective combination therapeutic strategies that limit resistance.Significance:Elucidation of the features of the drug-tolerant persister state in triple-negative breast cancer reveals shared programs across patients and treatments that offer opportunities to prevent persistence and delay tumor recurrence.
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Characterization of Drug-Tolerant Persister Cells in Triple-Negative Breast Cancer Identifies a Shared Persistence Program across Treatments and Patients
Acquisition of resistance to anticancer therapies is a multistep process initiated by the survival of drug-tolerant persister cells. Accessibility of drug-tolerant persister cells in patients is limited, which has hindered understanding the mechanisms driving their emergence. In this study, using multiple patient-derived models to isolate persister cells, we showed that these cells are transcriptionally plastic in vivo and return to a common treatment naïve–like state upon relapse, regardless of treatment. Hallmarks of the persister state in triple-negative breast cancer (TNBC) across treatment modalities included high expression of basal keratins together with activation of stress response and inflammation pathways. These hallmarks were also activated in HER2+ breast and lung cancer cells in response to targeted therapies. Analysis of gene regulatory networks identified AP-1, NF-κB, and IRF/STAT as the key drivers of this hallmark persister state. Functionally, FOSL1, an AP-1 member, drove cells to the persister state by binding enhancers and reprogramming the transcriptome of cancer cells. On the contrary, cancer cells without FOSL1 had a decreased ability to reach the persister state. By defining hallmarks of TNBC persistence on multiple therapies, this study provides a resource to design effective combination therapeutic strategies that limit resistance.Significance:Elucidation of the features of the drug-tolerant persister state in triple-negative breast cancer reveals shared programs across patients and treatments that offer opportunities to prevent persistence and delay tumor recurrence.